443 related articles for article (PubMed ID: 25249260)
41. The effect of laterality and primary tumor site on cancer-specific mortality in breast cancer: a SEER population-based study.
Bao J; Yu KD; Jiang YZ; Shao ZM; Di GH
PLoS One; 2014; 9(4):e94815. PubMed ID: 24740002
[TBL] [Abstract][Full Text] [Related]
42. Basal-like breast cancer defined by FOXC1 expression offers superior prognostic value: a retrospective immunohistochemical study.
Ray PS; Bagaria SP; Wang J; Shamonki JM; Ye X; Sim MS; Steen S; Qu Y; Cui X; Giuliano AE
Ann Surg Oncol; 2011 Dec; 18(13):3839-47. PubMed ID: 21424368
[TBL] [Abstract][Full Text] [Related]
43. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
44. Older Patients With Early-stage Breast Cancer: Adjuvant Radiation Therapy and Predictive Factors for Cancer-related Death.
Nagar H; Yan W; Christos P; Chao KSC; Nori D; Ravi A
Am J Clin Oncol; 2017 Jun; 40(3):300-305. PubMed ID: 25333731
[TBL] [Abstract][Full Text] [Related]
45. Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark.
Christiansen P; Bjerre K; Ejlertsen B; Jensen MB; Rasmussen BB; Lænkholm AV; Kroman N; Ewertz M; Offersen B; Toftdahl DB; Møller S; Mouridsen HT;
J Natl Cancer Inst; 2011 Sep; 103(18):1363-72. PubMed ID: 21881042
[TBL] [Abstract][Full Text] [Related]
46. Prognostic factors for stage IV hormone receptor-positive primary metastatic breast cancer.
Kawano A; Shimizu C; Hashimoto K; Kinoshita T; Tsuda H; Fujii H; Fujiwara Y
Breast Cancer; 2013 Apr; 20(2):145-51. PubMed ID: 22139727
[TBL] [Abstract][Full Text] [Related]
47. Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis.
Morikawa A; Jordan L; Rozner R; Patil S; Boire A; Pentsova E; Seidman AD
Clin Breast Cancer; 2017 Feb; 17(1):23-28. PubMed ID: 27569275
[TBL] [Abstract][Full Text] [Related]
48. Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes.
Kim HJ; Kwon H; Lee JW; Kim HJ; Lee SB; Park HS; Sohn G; Lee Y; Koh BS; Yu JH; Son BH; Ahn SH
Breast Cancer Res; 2015 May; 17(1):64. PubMed ID: 25935404
[TBL] [Abstract][Full Text] [Related]
49. Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry.
Zell JA; Tsang WY; Taylor TH; Mehta RS; Anton-Culver H
Breast Cancer Res; 2009; 11(1):R9. PubMed ID: 19228416
[TBL] [Abstract][Full Text] [Related]
50. Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer.
Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Aishima S; Morita M; Kakeji Y; Maehara Y
Ann Surg Oncol; 2012 Apr; 19(4):1145-52. PubMed ID: 21984487
[TBL] [Abstract][Full Text] [Related]
51. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
[TBL] [Abstract][Full Text] [Related]
52. Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26-30.
Park S; Han Y; Liu Y; Toriola AT; Peterson LL; Colditz GA; Kim SI; Cho YU; Park BW; Park Y
Breast Cancer Res; 2019 Oct; 21(1):110. PubMed ID: 31619259
[TBL] [Abstract][Full Text] [Related]
53. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
[TBL] [Abstract][Full Text] [Related]
54. Prognostic markers for invasive micropapillary carcinoma of the breast: a population-based analysis.
Chen AC; Paulino AC; Schwartz MR; Rodriguez AA; Bass BL; Chang JC; Teh BS
Clin Breast Cancer; 2013 Apr; 13(2):133-9. PubMed ID: 23246269
[TBL] [Abstract][Full Text] [Related]
55. HR+/Her2- breast cancer in pre-menopausal women: The impact of younger age on clinical characteristics at diagnosis, disease management and survival.
De Camargo Cancela M; Comber H; Sharp L
Cancer Epidemiol; 2016 Dec; 45():162-168. PubMed ID: 27846443
[TBL] [Abstract][Full Text] [Related]
56. Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients - results from a large single-centre analysis.
Hartkopf AD; Taran FA; Wallwiener M; Hahn M; Becker S; Solomayer EF; Brucker SY; Fehm TN; Wallwiener D
Eur J Cancer; 2014 Oct; 50(15):2550-9. PubMed ID: 25096167
[TBL] [Abstract][Full Text] [Related]
57. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis.
Leone JP; Leone J; Zwenger AO; Iturbe J; Leone BA; Vallejo CT
Eur J Cancer; 2017 Mar; 74():17-25. PubMed ID: 28335884
[TBL] [Abstract][Full Text] [Related]
58. Prognostic factors for triple-negative breast cancer patients receiving preoperative systemic chemotherapy.
Asaga S; Kinoshita T; Hojo T; Suzuki J; Jimbo K; Tsuda H
Clin Breast Cancer; 2013 Feb; 13(1):40-6. PubMed ID: 23103363
[TBL] [Abstract][Full Text] [Related]
59. Is there a cause-specific survival benefit of postmastectomy radiation therapy in women younger than age 50 with T3N0 invasive breast cancer? A SEER database analysis: outcomes by receptor status/race/age: analysis using the NCI Surveillance, Epidemiology, and End Results (SEER) database.
Yan W; Christos P; Nori D; Chao KS; Ravi A
Am J Clin Oncol; 2013 Dec; 36(6):552-7. PubMed ID: 22868241
[TBL] [Abstract][Full Text] [Related]
60. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study.
Schwentner L; Wolters R; Koretz K; Wischnewsky MB; Kreienberg R; Rottscholl R; Wöckel A
Breast Cancer Res Treat; 2012 Apr; 132(3):1073-80. PubMed ID: 22205141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
